BioLineRx (BLRX) Cash from Investing Activities Growth (3y) (2016 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 116.52% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.24% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -22.09% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 30.54% |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | -27.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -27.80% |
| Sep 30, 2025 | 30.96% |
| Jun 30, 2025 | -33.31% |
| Mar 31, 2025 | -53.54% |
| Dec 31, 2024 | 40.79% |
| Sep 30, 2024 | 533.61% |
| Jun 30, 2024 | -12.94% |
| Mar 31, 2024 | 35.00% |
| Dec 31, 2023 | -63.71% |
| Sep 30, 2023 | -18.41% |
| Jun 30, 2023 | 58.47% |
| Mar 31, 2023 | 2.37% |
| Dec 31, 2022 | 6.57% |
| Sep 30, 2022 | -69.60% |
| Jun 30, 2022 | 17.45% |
| Mar 31, 2022 | 36.48% |
| Dec 31, 2021 | 37.87% |
| Sep 30, 2021 | -80.29% |
| Jun 30, 2021 | -61.76% |
| Mar 31, 2021 | -86.49% |
| Dec 31, 2020 | 33.32% |
| Sep 30, 2020 | 60.51% |
| Jun 30, 2020 | 31.39% |
| Mar 31, 2020 | 65.45% |
| Dec 31, 2019 | 17.18% |
| Sep 30, 2019 | 18.42% |
| Jun 30, 2019 | 34.65% |
| Mar 31, 2019 | -96.87% |
| Dec 31, 2018 | -59.71% |
| Sep 30, 2018 | 102.25% |
| Jun 30, 2018 | -1.32% |
| Mar 31, 2018 | 33.72% |
| Dec 31, 2017 | 42.23% |
| Sep 30, 2017 | -186.62% |
| Jun 30, 2017 | -89.85% |
| Mar 31, 2017 | 27.48% |
| Dec 31, 2016 | 94.13% |
| Sep 30, 2016 | 47.53% |
| Jun 30, 2016 | -25.32% |
| Mar 31, 2016 | 28.82% |